78868
document
The treatment of localized non-Hodgkin 's lymphoma in children : a report from the Children 's Cancer Study Group . Investigators of the Children 's Cancer Study Group entered 73 children with previously untreated localized non-Hodgkin 's lymphoma on a prospective randomized trial of systemic treatment with either a four-drug program ( cyclophosphamide , vincristine , methotrexate , prednisone [ COMP ] ) or a 10-drug ( LSA2-L2 modified ) program of 18 months duration . All patients received central nervous system prophylaxis with intrathecal methotrexate and most received local or regional radiation treatment . The three-year relapse-free survival rate for all patients ( N = 73 ) was 84 % ; for COMP ( N = 42 ) was 85 % , and for LSA2-L2 ( N = 31 ) was 84 % . Of the 12 patients who suffered adverse events eight relapsed and four died of toxicity . Histopathology was reviewed centrally . Of 32 patients with nonlymphoblastic disease treated with COMP only one relapsed . Of 26 patients treated with LSA2-L2 , four relapsed . Patients with localized lymphoblastic disease were uncommon . None of three patients treated with LSA2-L2 relapsed compared with three of nine treated with COMP . COMP is an excellent treatment for patients with localized disease of nonlymphoblastic type , but the relative value of the two regimens for patients with localized lymphoblastic disease is uncertain .
78869
Intervention_Pharmacological
cyclophosphamide , vincristine , methotrexate , prednisone [ COMP ] )
78870
Intervention_Pharmacological
10-drug ( LSA2-L2 modified )
78871
Intervention_Pharmacological
central nervous system prophylaxis with intrathecal methotrexate
78872
Intervention_Physical
local or regional radiation treatment
78873
Intervention_Pharmacological
COMP
78874
Intervention_Pharmacological
LSA2-L2
78875
Intervention_Pharmacological
LSA2-L2
78876
Intervention_Pharmacological
COMP
78877
Outcome_Mortality
three-year relapse-free survival rate
78878
Outcome_Adverse-effects
adverse events
78879
Outcome_Other
relapsed
78880
Outcome_Mortality
died of toxicity
78881
Outcome_Physical
relapsed
78882
Outcome_Physical
relapsed
78883
Outcome_Physical
localized lymphoblastic disease